Trial Condition(s):

Secondary Peritonitis, Abscess, Intra-Abdominal

Moxifloxacin i.v. in the treatment of Complicated Intra-Abdominal Infection (cIAI)

Bayer Identifier:

14537

ClinicalTrials.gov Identifier:

NCT01096511

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Inclusion Criteria
- Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered.
Exclusion Criteria
- Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.

Trial Summary

Enrollment Goal
1001
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, China

Status
Completed
 

Trial Design